Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards Lifesciences's Ending Cash Position for the quarter that ended in Mar. 2026 was €2,117 Mil.
Edwards Lifesciences's quarterly Ending Cash Position
increased
from Sep. 2025 (€2,296 Mil) to Dec. 2025 (€2,510 Mil) but then
declined
from Dec. 2025 (€2,510 Mil) to Mar. 2026 (€2,117 Mil).
Edwards Lifesciences's annual Ending Cash Position
increased
from Dec. 2023 (€1,053 Mil) to Dec. 2024 (€2,921 Mil) but then
declined
from Dec. 2024 (€2,921 Mil) to Dec. 2025 (€2,510 Mil).
Edwards Lifesciences Ending Cash Position Related Terms
Edwards Lifesciences Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Edwards Lifesciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of €2,117 Mil mean?
Edwards Lifesciences (WBO:EWLS) has a Ending Cash Position of €2,117 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Ending Cash Position too high?
Edwards Lifesciences' current Ending Cash Position is €2,117 Mil. Overall, Edwards Lifesciences has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Ending Cash Position compare to BSX and GEHC?
Edwards Lifesciences' Ending Cash Position of €2,117 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Ending Cash Position is €2,117 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (WBO:EWLS) is currently considered Modestly Undervalued. The stock's GF Value™ is €82.51, compared to a current price of €74.16 — trading 10.1% below its estimated fair value. The current Ending Cash Position is €2,117 Mil. Edwards Lifesciences' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Edwards Lifesciences (WBO:EWLS), the current Ending Cash Position is €2,117 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (WBO:EWLS) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of €74.16 is trading 10.1% below its estimated GF Value™ of €82.51.
GuruFocus considers Edwards Lifesciences to be Modestly Undervalued.
Key valuation signals for WBO:EWLS:
Ending Cash Position: €2,117 Mil
GF Value™: €82.51 vs. price of €74.16 (10.1% below fair value)
No single metric tells the full story. See the WBO:EWLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
94GF Score
Get the complete analysis for WBO:EWLS
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:EWLS has been successfully added to your 
